RC48-ADC For Metastatic Urothelial Carcinoma With HER2-Positive: Combined Analysis of RC48-C005 and RC48-C009 Trials ASCO 2022: A Phase II Study of RC48-ADC in HER2-Negative Patients With Locally ...

而随着药企的不断布局，未来，ADC 药物将不仅在乳腺癌、淋巴瘤、白血病等现有治疗领域进一步巩固地位，还将拓展到更多癌症类型的治疗。同时，随着技术的不断成熟和成本的降低， ADC 药物的市场将进一步提高。 返回搜狐，查看更多 ...

After hours: March 13 at 6:55:15 PM EDT Loading Chart for ADC ...

A Phase II Study of RC48-ADC in HER2-Positive Patients with Locally Advanced or Metastatic Urothelial Carcinoma - Medical Oncologist Perspective ASCO 2019: Cardiovascular Morbidity in a Randomized ...

随着2024年全球生物医药行业的回暖，创新药投资重新加速，ADC（抗体偶联药物）等新兴领域崛起，带动CRO/CDMO市场进入新一轮增长期。皓元医药正是这一轮行业复苏中的关键受益者，其在ADC产业链的提前布局使其迅速脱颖而出。

After hours: March 13 at 6:00:06 PM EDT Loading Chart for ADCT ...